Although postoperative immunohistochemistry, MYC gene amplification on molecular testing, and disease progression were consistent with the characteristics of GBM-PNC, the absence of corresponding morphological evidence led to a diagnosis of GBM NOS, World Health Organization grade IV. Here, MYC is linked to glioblastoma.